Form 4: Amicus Therapeutics CPO Sells Shares Under 10b5-1 Plan

Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,642 shares of common stock for $14.1713 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• David Michael Clark, Chief People Officer of Amicus Therapeutics, Inc. (FOLD), reported a sale of common stock.
• The transaction involved the disposition of 25,642 shares of common stock.
• The shares were sold at a price of $14.1713 per share.
• The transaction date was December 19, 2025.
• Following this transaction, Clark beneficially owns 245,690 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on March 14, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction executed under a pre-arranged 10b5-1 trading plan, which typically indicates personal financial planning rather than a change in company fundamentals or outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine part of executive compensation and personal financial management across all industries, including the biotechnology and pharmaceutical sectors where Amicus Therapeutics operates. These pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders may note the insider sale, which, while pre-planned, can sometimes be perceived with caution, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Insider Sale, Form 4, David Michael Clark, Chief People Officer, 10b5-1 plan, Common Stock